Ibio, Inc. · NASDAQ:IBIO
Ibio — Investor Presentation (October 2024)
72 slides from Ibio's investor presentation, Oct 23, 2024
Slide 1: Tomorrow's Precision Antibody Therapeutics Powered by Machine Learning
October 2024 Tomorrow’s Precision Antibody Therapeutics Powered by Machine Learning
Slide 2: Forward-looking Statements
2 Forward-looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continu
Slide 3: Next Generation Antibody Company with Machine Learning Antibody Engine
*U.S. Patent No. 11,545,238 (issued January 3, 2023) https://www.globenewswire.com/news-release/2023/09/06/2738625/0/en/Monoclonal-Antibodies-Market-is-expected-to-reach-USD-612-2-Billion-by-2032-growing-at-a-CAGR-of-12-3-from-2022-to-2032.html 3 Next Generation Antibody company utilizing our propri
Slide 4: Evolution of iBio: From CDMO to Machine-Learning Enabled Antibody Discovery
4 2008-2020 Post Sept 2022 2023 Plant-Based CDMO & COVID Vaccine Focus Machine Learning Biotech Transformation Biotech Strategy Execution Entering Metabolic Disease Space Building a Leading Biologics Company • New Exec. Team • Raised $15.1M • Eli Lilly Partnership • NIH Collaboration • 3 Undisclosed
Slide 5: Innovating with Intelligence: Unleashing Our AI-Driven Antibody Discovery
5 • Patented epitope-engineering technology • StableHu antibody optimizer coupled with mammalian display • EngageTx next generation bi-specific antibody platform • ShieldTx antibody masking fully integrated in technology stack Technology Stack Spurs Rapid Preclinical Pipeline • Pipeline of 6 preclin
Slide 6: Challenges of Antibody Discovery and Development
Increase Low Overall Success Rate Compress Time From Discovery to IND Design mAbs with Complex MoA Pursuit of Novel Biology & Targets 6 Challenges of Antibody Discovery and Development Requires Integration of Individual Point Solutions 1. Ingelheim, B. Drug Discovery at Boehringer Ingelheim. Boehrin
Slide 7: iBio's Generative AI-Driven Tech Stack
*U.S. Patent No. 11,545,238 (issued January 3, 2023) 7 iBio’s Generative AI-Driven Tech Stack - Integrated Solution for Antibody Discovery & Development Improved Developability Accelerated Discovery Time mAbs with Complex MoA Epitope Engineering AI Engine* Engineered Epitope AI-Guided Precision Hit
Slide 8: ML Technology Accelerates Preclinical Pipeline
8 ML Technology Accelerates Preclinical Pipeline † Patent Pending *Developed with Engage Tx bispecific platform PROGRAMS EARLY DISCOVERY LATE DISCOVERY LEAD OPTIMIZATION IND-ENABLING MODE OF ACTION - TARGET CARDIO-METABOLIC Collaboration with AstralBio Established March 2024 Myostatin Soluble factor
Slide 9: Our Generative AI Platform: Endorsed by Leading Partners
9 Our Generative AI Platform: Endorsed by Leading Partners PD-1 Agonist Asset Acquired by Otsuka; $52.5M Potential Milestone Payments Completed R&D Collaboration to Develop Lassa Fever Vaccine Undisclosed >$1Bn Market Cap mAb Company Eli Lilly R&D Agreement, Option to License Antibodies Against Two
Slide 10: Seizing Future Opportunities: Growing Pipeline and Strategic Collaborations
iBio Internal Pipeline Partnership Data Programs Data Programs 10 Seizing Future Opportunities: A Growing Pipeline and Strategic Collaborations Driving Platform Development Rapidly Evolving Obesity/Cardiometabolic Pipeline • Strong Focus on Validated Biology • Generative AI Platform to Engineer Best
Slide 11: Anticipated Collaboration Catalysts
11 Anticipated Collaboration Catalysts 2024 2025 2026 2027 JAN JUN DEC JAN JUN DEC JAN JUN DEC JAN Cardio-metabolic Pipeline Collaboration with AstralBio Established March 2024 Myostatin (Obesity) Target 2 (Obesity) Target 3 (Obesity) Partnerships Eli Lilly Lead Selection Development Candidate IND-E
Slide 12: Led by Industry Veterans, Powered by Next-Gen Scientists
12 Led by Industry Veterans, Powered by Next-Gen Scientists Leadership Team Martin Brenner, DVM, Ph.D. CEO & CSO Marc Banjak CLO Leadership team with decades of experience in pharma / biotech industry and extensive deal and fund-raising expertise Scientific team of new generation “bi-lingual” scient
Slide 13: iBio Summary: Company and Financial Highlights
13 Company Highlights Financial Highlights iBio Summary • Patented machine learning technology solving hard to drug molecule challenges • Numerous validating partnerships showing proof of concept • Developing novel targets in the Obesity/Cardiometabolic space • Best in class fast follower I/O pipeli
Slide 14: Appendix
Appendix 14
Slide 15: Technology Platform & Preclinical Pipeline
Technology Platform & Preclinical Pipeline 15
Slide 16: iBio Technology Stack
iBio Technology Stack 16
Slide 17: iBio's Tech Stack Aims to Solve Major Challenges in Antibody Discovery
17 iBio’s Tech Stack Aims to Solve Major Challenges in Antibody Discovery & Development Epitope Steering StableHu & Mammalian Display Unlocking Novel Biology Reduced Lead-Optimization Time Optimization in less than 4 weeks Minimized Developability Risk Mammalian Display in Manufacturing Cell Line Po
Slide 18: Tech Stack Addresses Immuno-oncology Discovery and Development Challenges
18 iBio’s Tech Stack Addresses Immuno-oncology Discovery and Development Challenges ShieldTx 2nd Gen T-cell Engager Panel Finely tuned T-cell engagement Adjustable T-cell engagement to fit any tumor target engager Improved safety prediction Cyno cross reactivity allows for better preclinical safety
Slide 19: AI-Engineered Epitopes Unlocking High-Value Drug Targets
Match Engineered Structure to Target Refined for Greater Stability Optimized for Water Solubility Unlocking High-Value Drug Targets: AI-Engineered Epitopes are Generalizable to a Broad Set of Complex Structural Drug Binding Sites Junctional Epitopes Complex Secondary Structures Membrane Proteins (e.
Slide 20: StableHu Antibody Optimization & Mammalian Display Screening
Input Antibody StableHu AI-Engine Mammalian Display Output Antibody Template CDR Predict library of human CDR variants Single-cell screen mammalian display CDR library Optimized antibody with fully human CDRs Accelerate Success: StableHu Antibody Optimization & Mammalian Display Screening Propel Fas
Slide 21: Smart Antibodies: ShieldTx Conditionally Activated Antibodies
21 “Smart” Antibodies: ShieldTx Conditionally Activated Antibodies Strive to Improve Safety by Selectively Targeting Diseased but not Healthy Tissue H+ Diseased Tissue “On-epitope, off-tissue” therapy Healthy Tissue “On-epitope, on-tissue” therapy DME activation Diseased Tissue “On epitope, on tissu
Slide 22: EngageTx, a CD3-Based T-Cell Engager Panel
22 EngageTx, a CD3-Based T-Cell Engager Panel, Addresses 3 Key Challenges: Cytokine Release, NHP Cross-Reactivity and Immunogenicity Risk Numerous tumor antigen arms Diverse CD3 engager arms 1 Sequence Diversity 2 Hu-Cyno Cross-Reactivity 3 Range of Cytokine Release Increased humanness and broad CD3
Slide 23: iBio's Platform Tackles Discovery Challenges for the Next Era of Antibodies
Epitope Engineering Engine* Proprietary Antibody Library AI-powered mammalian-display co-optimization of mono/multi-specific antibody and conditionally activated mask Engineered Epitope Steering AI-powered engineering of conformational epitopes Epitope-specific antigens that steer discovery to inten
Slide 24: Long-Acting Anti-Myostatin
24 Long-Acting Anti-Myostatin
Slide 25: Myostatin Antagonism
1. Gross, K. and Brinkmann, C. (2024) Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss. Frontiers in Endocrinology, (15) 2. Schuelke, M., et al (2004). Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child. New England Journal of M
Slide 26: Anti-Myostatin Antibody Promotes Muscle Fiber Formation in Human Progenitor Cells
26 iBio Anti-Myostatin Antibody Promotes Muscle Fiber Formation in Human Muscle Progenitor Cells Red indicates marker for muscle cell growth and development (as measured by myoblast differentiation) Control + Myostatin + Myostatin + iBio Anti-Myostatin mAb
Slide 27: Half-life Extended Myostatin Antagonist Monoclonal Antibody
27 Half-life Extended Myostatin Antagonist Monoclonal Antibody Key Insights Fundamental Concepts Application Myostatin Inhibition Established as an Effective Mechanism to Increase & Preserve Muscle Mass First-generation Myostatin Binders Lacked Specificity Agents were Developed for Severe Conditions
Slide 28: Half-life Extended Myostatin Antagonist: Best-In-Class Profile
Half-life Extended Myostatin Antagonist Monoclonal Antibody 28 Best-In-Class Profile • Leverages Fc engineering with potentially class-leading properties • Sequence leverages iBio’s Tech Stack with a known antibody that has been in ~500 patients • Demonstrated activity, safety and low-volume subcuta
Slide 29: IBIO-101 IL-2 Sparing Anti-CD25
29 IBIO-101 IL-2 Sparing Anti-CD25
Slide 30: IBIO-101 for Regulatory T-Cell Depletion
Recent Transactions & Milestones *Roche acquisition of Tusk Therapeutics completed for €70M upfront, acquiring worldwide rights to anti-CD25 program. Values converted to dollars as reported in public press releases **Data presented by Roche at AACR 2023 30 IBIO-101 for Regulatory T-Cell (Treg) Deple
Slide 31: IBIO-101 Reduces Tumor Growth by Selectively Depleting Tregs
Data on file. Treg = Regulatory T Cells; Teff = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity 31 IBIO-101 Reduces Tumor Growth in Preclinical Studies by Selectively Depleting Immunosuppressive Tregs without Affecting Cancer Killing Teffs Indiscriminate depletion of Treg + Teff TU
Slide 32: IBIO-101 Selectively Depletes Tregs while Preserving IL-2 Signaling
RG6292 is Roche’s monoclonal antibody that targets CD25 (IL-2Rα). IBIO-101 data on file. 32 IBIO-101 Selectively Depletes Tregs while preserving IL-2 signaling IBIO-101 potently binds recombinant CD25 which leads to Treg depletion while sparing Teffs
Slide 33: IBIO-101 Increases Teff/Treg Ratio in Preclinical Studies
33 IBIO-101 Increases in Teff/Treg Ratio in Preclinical Studies Inhibiting Tumor Growth Tumor growth inhibition correlates with T-eff/T-reg ratio Potently increases T-eff/T-reg ratio1 1hCD25 animal model - Data on file. * Significant vs * Significant vs Negative Control hIgG1 Isotype
Slide 34: IBIO-101 in Combination With a Checkpoint Inhibitor
34 IBIO-101 in Combination With a Checkpoint Inhibitor Shows Greater Efficacy IBIO-101 + PD-1 Checkpoint Inhibitor In PreClinical Studies Enhances Tumor Suppression *hCD25 animal model - Data on file. * Significant vs Negative Control # Significant vs Anti-PD-1
Slide 35: IBIO-101 Favorable Characteristics for CMC Development
35 IBIO-101 is an Antibody With Favorable Characteristics for CMC Development • Identified manufacturing partner to produce IBIO-101 for Phase 1&2 clinical trials • Discovered suitable cell lines for manufacturing MCB • Established IBIO-101 CMC methodology for producing high yield, high purity, stab
Slide 36: Anti-CCR8 High ADCC
36 Anti-CCR8 High ADCC Anti-CCR8 for the Depletion of T-regulatory Cells
Slide 37: CCR8 for Tumor-Infiltrating Treg Depletion
*Fibrogen / HiFiBio: Fibrogen purchased option to multiple programs in June 2021, then exercised the option for excl. license to CCR8 program in Dec. 2021. **Gilead / Jounce: Exclusive worldwide license to anti-CCR8 antibody. *** Coherus / Surface Oncology: acquisition, announced in June 2023, adds
Slide 38: CCR8+ Treg Cells Are Tumor Infiltrating and Highly Immunosuppressive
Zheng, et al. Cell 169.7 (2017): 1342-1356; Whiteside, et al. Immunology 163(4) (2021): 512-520; Kidani, et al. PNAS 119(7) (2022): e2114282119 38 CCR8+ Treg Cells Are Tumor Infiltrating and Highly Immunosuppressive Depletion of CCR8+ Treg cells has potential to evoke potent tumor immunity • Systemi
Slide 39: Afucosylated Anti-CCR8 Antibody Specificity and Cell Killing
Data on file 39 Afucosylated Anti-CCR8 Antibody Exhibits High Specificity, CCL1 Antagonism and CCR8-Specific Cell Killing High Specificity CCR8 Cell Binding 0.0001 0.001 0.01 0.1 1 10 0 2 4 6 8 10 hCCR8 overexpressed cells Ab. (nM) MFI hIgG1 isotype mIgG2A isotype Anti -hCCR4 - EC50 = NA Anti-mCCR8
Slide 40: CCR8-Specific High ADCC Antibody Induces Tumor Regression in Mouse Model
40 iBio’s CCR8-Specific High ADCC Antibody Induces Tumor Regression in a Transgenic Human CCR8 Mouse Model Day -7 Day 0 Day 0, 3, 7, 10 Tumor implantation Subsequent dosing Test article dosing (i.p) 0 2 4 6 8 10 12 14 0 50 100 150 200 250 300 Days after treatment Tumor Volume (mm3 ) * * * * p<0.05 v
Slide 41: Bi-Specific Antibodies with EngageTx CD3 mAb Panel
41 Unlocking the Power of Bi-Specific Antibodies with EngageTx, Our Versatile CD3 mAb Panel Wide Range of Affinities, NHP Cross Reactivity, High Developability
Slide 42: Next Generation Anti-CD3 T Cell Engagers
*Eli Lilly / Merus: Fibrogen Research collaboration using Merus’ proprietary platform to develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. ** GSK WuXi: License of WuXi’s preclinical CD3 bi-specific, plus 3 earlier stage programs ***Amgen / Teneobio: Teneobio was dev
Slide 43: Dual Approaches to a Diverse Panel of Anti-CD3 Antibodies
Data on file 43 Dual Approaches to a Diverse Panel of Anti-CD3 Antibodies Hu/Cyno CD3 & T Cell TCR CD3 Engineered Epitopes T Cell Template 1 Template 2 Structural-Epitope Immunization & Screening StableHu Optimizer AI Discovery Engine AI-Engineered Immunogens Epitope & T Cell Immunization Epitope &
Slide 44: Libraries and Screens Discover Hu-Cyno CD3 Cross-Reactive Antibodies
Data on file 44 Libraries and Screens Discover Hu-Cyno CD3 Cross-Reactive Antibodies Epitope-Steered Immunization Human T Cell Binding Selected Hit Low Medium High StableHu Mammalian-Display Not Selected Library Screen:
Slide 45: EngageTx Selected for Diversity of T Cell Binding and Activation
Data on file 45 EngageTx is Selected for a Diversity of T Cell Binding and Activation EC50: 3 – 570 nM EC50: 2.5 – 70 nM Human T Cell Binding EC50 (nM) CD69 T Cell Activation EC50 (nM) Hit Clones Hit Clones T Cell Assay: Ab Concentration (nM) IFN-γ (pg/mL) TNF-⍺ (pg/mL) IL-2 (pg/mL) ID 1 2 3 5 (-) C
Slide 46: ShieldTx Antibody Masking Technology
46 ShieldTx Antibody masking technology for delivering on-epitope, on-tissue clinical candidates with enhanced safety and developability
Slide 47: On-Target-Off-Tissue Side Effects Limit Existing and Future Antibodies
Diseased Tissue Healthy Tissue 47 On-Target-Off-Tissue Side Effects Severely Limit The Potential of Existing And Future Antibodies Even exquisitely specific antibodies fail in clinical trials by doing exactly what they are asked to do – hit the target. The problem often lies in the target being also
Slide 48: Engineered Epitopes Provide Integrated Solution for Masking Antibodies
48 Our Engineered Epitopes Provide an Integrated Solution for Identifying And Subsequently Masking Antibodies Diseased Tissue “On-epitope, off-tissue” therapy Healthy Tissue DME activation “On-epitope, on-tissue” therapy H+ DME: Disease Micro Environment Antibodies are activated by the removal of th
Slide 49: Masked Antibodies are a Proven Concept; iBio Platform Solves Key Challenges
Masked Antibodies are a Proven Concept and iBio’s Platform has the Potential to Solve Key Remaining Challenges 49 THE PROBLEM OUR SOLUTION 1 Separate antibody and mask discovery process is inefficient Co-discovery of epitope-steered antibody and mask is more efficient Discovery process 2 Separate di
Slide 50: Conditionally Activated Anti-MUC16 x CD3 Bispecific Antibodies
50 Conditionally Activated Anti-MUC16 x CD3 Bispecific Antibodies Targeting the Non-Shed MUC16 Region Leveraging iBio’s Epitope Steering, ShieldTx, and EngageTx Technologies
Slide 51: MUC16 Potentially for Ovarian and Other Cancers
+Regeneron MUC16xCD3 (Sept 2022): Ph. 1 31% ORR Ph. 2 enrollment 51 MUC16 Potentially for Ovarian and Other Cancers Bind a membrane-proximal MUC16 epitope Membrane-proximal binding avoids epitope elimination by tumors Bind a non-glycosylated epitope to avoid altered glycosylation on tumors • Ovarian
Slide 52: MUC16 Is Overexpressed and Shed by Tumor Cells
52 MUC16 Is Overexpressed and Shed by Tumor Cells O-glycosylation N-glycosylation MUC16 epitope shedding Shedding eliminates the epitope and creates an antigen sink for most MUC16 antibodies Antibodies that bind the non-shed domain maintain activity N-terminal and tandem repeat (TR) domains that are
Slide 53: Immunizations Steered to a MUC16 Epitope that Avoids Shedding
Weeks 1–2 Weeks 3–4 Week 5 53 Immunizations Were Steered to a MUC16 Epitope that Avoids Epitope Shedding Engineered Epitope Prime + MUC16 Cell Boost AI Discovery Engine MUC16 Engineered Epitope Structural-epitope Immunization & Screening Engineered Epitope ELISA Screen MUC16 OVCAR-3 MUC16high Cell B
Slide 54: Top Three Hit Clones Bind Non-Glycosylated MUC16 Epitope
54 Top Three Hit Clones Bind the Non-Glycosylated MUC16 Epitope Closest to the Membrane 1D7 8G4 21G6 Hits do not bind shed 230-mer Hits bind non-glycosylated non-shed 29-mer binding time O-glycosylation N-glycosylation N-terminal and tandem repeat (TR) domains that are shed Epitope KD = 8.0 nM KD =
Slide 55: Top MUC16 Clone 8G4 Binds OVCAR-3 Cells Comparable to Benchmark
55 Top MUC16 Clone 8G4 Binds OVCAR-3 Cells Comparable to Regeneron Benchmark Regeneron benchmark Clone ID: Secondary Only Unstained OVCAR-3 Cells 8G4 top clone higher cell binding Mode Normalized Data on file
Slide 56: 8G4 Clone Maintains Binding in a Fully Human Framework
56 8G4 Clone Maintains OVCAR-3 Cell and MUC16 Epitope Binding in a Fully Human Framework 8G4 with fully human framework reduces immunogenicity risk Glycosylated MUC16 membrane-proximal epitope SPR: KD = 5.1 nM Iso. Ctl OVCAR-3 Cells Epitope binding Cell binding higher cell binding Data on file
Slide 57: Efficient Expression with 2x2 Format Anti-CD3 x MUC16
57 Efficient Expression with 2x2 Format: Anti-CD3 x MUC16 Bispecific T-Cell Engagers scFv-Fc 2x2 Anti-MUC16 TAA Anti-CD3 (EngageTx) CD3 MUC16 TAA T Cell Tumor Cell T Cell mediated killing
Slide 58: 2x2 Anti-CD3 x MUC16 T Cell Engagers Stimulate T Cells
EC50 = 14 nM EC50 = 62 nM EC50 = 19 nM EC50 = 126 nM Data on file 58 2X2 Anti-CD3 X MUC16 T Cell Engagers Stimulate T Cells in Donor PBMCs EC50 >> 100 nM EC50 >> 100 nM MUC16 Arm 1 (-)CD3 Arm only Epitope-Steered Immunized Hit StableHu Hit CD69 MFI Concentration (nM) MUC16 Arm 2 CD3 Arms MUC16 Arms
Slide 59: 2x2 Anti-CD3 x MUC16 T Cell Engagers Kill OVCAR-3 Cells
EC50 = 4.0 nM EC50 = 2.5 nM EC50 = 5.2 nM EC50 = 5.2 nM Data on file 59 2X2 Anti-CD3 X MUC16 T Cell Engagers Kill OVCAR-3 Ovarian Cancer Cells EC50 >> 100 nM EC50 >> 100 nM MUC16 Arm 1 (-)CD3 Arm only Epitope-Steered Immunized Hit StableHu Hit Concentration (nM) MUC16 Arm 2 CD3 Arms MUC16 Arms % Spe
Slide 60: ShieldTx Engineered Epitope Mask Conditionally Activates MUC16 and CD3 Hits
Data on file 60 ShieldTx Engineered Epitope Mask Conditionally Activates MUC16 and CD3 Hits Mask Cleavage No Mask Mask (–MMP9) Mask (+MMP9) MMP protease Engineered Epitope Mask Intact Inactive Antibody Active Antibody Anti-MUC16 hit Anti-CD3 hit MUC16 Binding Response CD3 Binding Response time (s)
Slide 61: Anti-Trop-2 x CD3 Bi-Specific Antibody
61 Anti-Trop-2 x CD3 Bi-Specific Antibody against Tumor-Specific Trop-2 Cancer Cells
Slide 62: Trop-2 x CD3 Bi-Specific Antibody Potentially for Head & Neck and Other Cancer
Recent transactions Target mechanism Potential indications Differentiation / opportunity Gilead acquired Immunomedics (Sept 2020): $21Bn Payment Trodelvy: Approval 62 Trop-2 x CD3 Bi-Specific Antibody Potentially for Head & Neck and Other Cancer Select killing cancer cells that up-regulate Trop-2 ex
Slide 63: Trop-2 x CD3 Bi-Specific Antibody Selective Target
Tumor cells show significantly increased Trop-2 expression Tumor cell death with high Trop-2 expression Trop-2 x CD3 binds to tumor cells Trop-2 x CD3 recruits T cells to kill tumor cells 63 Trop-2 x CD3 Bi-Specific Antibody Selective Target Overexpress Trop-2 Cancer Cells Trop-2 Tumor cell Healthy
Slide 64: Trop-2 x CD3 Potently Kills Tumor Cells with Low Cytokine Release
64 iBio’s Trop-2 x CD3 Bi-Specific Antibody Potently Kills Tumor Cells with Low Cytokine Release 64 0.0001 0.001 0.01 0.1 1 10 0 20 40 60 80 100 Ab (nM) % of Cell Killing ID EC50 (pM) Cmax (% killing) SD-753019 1.4 92% SD-231831 7.2 92% SD-753019 (Trop-2 x CD3SP34 Gen1) SD-231831 (Trop-2 x CD3iBio)
Slide 65: Single Dose Trop-2 x CD3 Induces Tumor Regression in Mouse Model
65 A Single Dose of iBio’s Bispecific Trop-2 x CD3 Antibody Induces Tumor Regression in a Humanized Mouse Cancer Model 0 7 14 0 50 100 150 200 250 Days after tumor implantation Tumor volume (mm 3 ) Vehicle SD-231831 (1 mg/kg) Trop-2 x CD3iBio * * * * p<0.05 vs vehicle Single dose SD-231831 36% tumor
Slide 66: Anti-EGFRvIII High ADCC mAb
66 Anti-EGFRvIII High ADCC mAb Against Tumor-Specific EGFRvIII Cells
Slide 67: EGFRvIII Potentially for Glioblastoma and Other Cancers
**Seagen / LAVA Therapeutics (Sep 2022): $50M upfront, $650M milestones ***Taiho / Cullinan Oncology (May 2022): $275M upfront, $130M milestones * Pierre Fabre / Scorpion: Scorpion licensed two preclinical-stage programs to Pierre Fabre which are targeted to specific EGFR mutations in lung cancer. *
Slide 68: Anti-EGFRvIII mAbs Selectively Kill EGFRvIII-Positive Tumor Cells
Skin toxicity No skin damage 68 iBio’s Anti-EGFRvIII mAbs Selectively Kill EGFRvIII-Positive Tumor Cells and Not EGFR1-Expressing Cells in Healthy Tissues iBio mAb binding specifically to EGFRvIII Tumor Size Reduction iBio mAb doesn’t bind to EGFR1 in skin Non-EGFRvIII specific mAb binds to EGFR1 in
Slide 69: EGFRvIII-Selective mAbs Kill Tumor Cells without Affecting Healthy Cells
69 iBio’s EGFRvIII-Selective mAbs Kill Tumor Cells without Affecting Healthy Cells iBio EGFRvIII mAbs bind recombinant EGFRvIII which leads to tumor cell killing but not binding wild-type EGFR1 and thus not affecting healthy cells Data on file
Slide 70: EGFRvIII-Specific Antibody Inhibits Tumor Growth in Xenograft Model
70 iBio’s EGFRvIII-Specific High-ADCC Antibody Inhibits Tumor Growth in an EGFRvIII Tumor Xenograft Mouse Model Day -7 Day 0 Day 0, 3, 8, 11, 14, 17 Tumor implantation Subsequent dosing Test article dosing (i.v.) 0 5 10 15 20 25 0 200 400 600 800 1000 1200 1400 1600 1800 Days after treatment Tumor V
Slide 71: Market-Tested Potential: Competitor Early-Stage Deals
71 Market-Tested Potential Competitor Early-Stage Deals Signal Promising Opportunities
Slide 72: Market-Tested Potential: Immuno-Oncology Early-Stage Deals
* Acquisition / Merger + License or collaboration 72 Market-Tested Potential: Immuno-Oncology Early-Stage Deals Pre-2020 2021 2022 2023 CCR8 Gilead / Jounce+: $85M upfront, $35M equity investment, $685M milestones SEP 2020 FEB 2021 PD-1 agonist Merck / Pandion*: acquired for $1.85B SEP 2018 Roche /